evipedia.ai ← Back to Review

Audit: QRS - Artichoke Extract for Health & Longevity

Audit conducted on 26/07/2026 07:07 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 83
Failed 0
N/A 8
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All content traces to the ER (dosing, standardization, tiers, markers, cadence, contraindications).
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 Cautious framing preserved (e.g., “early signals”, “speculative” tiers).
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 No strengthening/softening detected; pregnancy/breastfeeding kept in the stop gate as in the ER “avoid” list.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Categories map faithfully to the ER’s own sections.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No citations, IDs, NCTs, expert or brand names introduced.
1.6 The QRS does not introduce new attributions. 🟢 No attributions present.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Matches the ER’s measured, evidence-forward tone.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Tone is expert yet accessible.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents evidence, not prescriptions.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No advice-giving language.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Information-presenting throughout.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Plain language used; unavoidable technical terms are marker/standardization names.
2.8 Information is presented in a concise and very compact manner 🟢 Compact card layout.
2.9 It DOES NOT address the reader directly 🟢 No direct address.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing suits proactive adults.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Protocol/monitoring detail assumes committed audience.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not general-population framing.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Add-on framing reflects the audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 No “anti-aging” language present.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 Terminology is clinical/scientific.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed headings/labels present and unmodified.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 Full set of data-qrs-var spans present.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Template/website spans left intact.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No relevant ER section is empty.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Labels drawn from ER content.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Labels faithful to the ER.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji indicators; CSS/bold used.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content condensed to one page.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment is first element (lines 2-14).
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 YAML delimited by — at lines 3 and 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Inside HTML comment; not rendered.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values trimmed; only duration quoted (contains colon).
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename matches the source ER.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.7.02.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-0726-0700.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 Single-word nickname.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 4.8.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 4.8” with no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename matches the QRS file.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Frontmatter clean and consistent.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “Artichoke Extract for Health & Longevity - Quick Reference Sheet”.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “Artichoke Extract for Health & Longevity”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0726-0700 → 07/26/2026.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 4.8”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header carries only title and subline.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses the ER Conclusion (lines 476-480).
7.2 [at_a_glance] is no longer than 60 words 🟢 56 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each fact traces to the Conclusion.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Uses “add-on”, “blood fats”; no acronyms.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial citations.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No effect sizes/statistics.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from ER lines 329-345.
8.2 [stop_items] represent the Contraindications from the ER 🟢 Bile-duct obstruction, Asteraceae allergy, pregnancy/breastfeeding.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Each item is an <li>.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Trailing clauses (“— absolute contraindication”, etc.) stripped.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “(daisy/ragweed)” preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. 🟢 No ranking notation to normalize.
8.7 If no [stop_items] are present the section is left empty N/A Contraindications are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from ER lines 329-345.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Bile-duct obstruction and Asteraceae allergy correctly excluded.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Each item is an <li>.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 “— monitor”/”— caution” trailing clauses stripped.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example drug lists preserved and trimmed to fit.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. 🟢 No ranking notation to normalize.
9.7 If no [caution_items] are present the section is left empty N/A Key Interactions are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Derived from ER Therapeutic Protocol (lines 363-383).
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Dose, Standardization, Timing.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three actionable aspects are present.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All three action cells populated from the ER.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Cholesterol & Triglycerides, Digestive Relief, Fatty Liver.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 High (lipids) then medium (digestive, liver).
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three time-to-effect aspects are present.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 Values (6–12 wks, days–2 wks, 8–12 wks) derived from the ER.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Derived from ER Expected Benefits (lines 160-236).
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four tier variables populated.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Concise benefit names only.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals carried through.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers have items.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Derived from ER Potential Risks (lines 254-311).
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four tier variables populated.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Concise risk names only.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 “(Asteraceae Sensitivity)” and similar parentheticals stripped.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four tiers have items.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Derived from ER Monitoring Protocol (lines 430-447).
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All 8 markers (LDL, Total chol, HDL, TG, ALT, AST, fasting glucose, hs-CRP) listed.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 “Baseline, again at 8–12 weeks, then every 6–12 months”.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Derived from ER qualitative markers (lines 449-454).
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All 4 qualitative markers listed.

Issues 26/07/2026 07:07

Pass rate 100.00%. No issues found.